BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 23613406)

  • 21. The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer.
    Steinbakk A; Skaland I; Gudlaugsson E; Janssen EA; Kjellevold KH; Klos J; Løvslett K; Fiane B; Baak JP
    Am J Obstet Gynecol; 2009 Jan; 200(1):78.e1-8. PubMed ID: 18976730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
    Alkushi A; Köbel M; Kalloger SE; Gilks CB
    Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clusterin immunoexpression is associated with early stage endometrial carcinomas.
    Al-Maghrabi JA; Butt NS; Anfinan N; Sait K; Sait H; Bajouh O; Khabaz MN
    Acta Histochem; 2016 May; 118(4):430-4. PubMed ID: 27079858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
    Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
    Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
    Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
    Bonfitto VL; de Angelo Andrade LA
    Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade.
    Urabe R; Hachisuga T; Kurita T; Kagami S; Kawagoe T; Matsuura Y; Shimajiri S
    J Obstet Gynaecol Res; 2014 Mar; 40(3):812-9. PubMed ID: 24246002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
    Demopoulos RI; Mesia AF; Mittal K; Vamvakas E
    Int J Gynecol Pathol; 1999 Jul; 18(3):233-7. PubMed ID: 12092593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
    Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
    Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
    Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
    Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical expression of galectin-3 is significantly associated with grade, stage and differentiation of endometrial carcinomas.
    Al-Maghrabi J; Abdelrahman AS; Ghabrah T; Butt NS; Al-Maghrabi B; Khabaz MN
    Pathol Res Pract; 2017 Apr; 213(4):348-352. PubMed ID: 28215640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
    Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
    Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
    Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
    Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The combination of p53 and age predict cancer specific death in advanced stage (FIGO Ic-IV) of endometrial carcinoma of endometrioid type. An immunohistochemical examination of growth fraction: Ki-67, MIB-1 and PC10; suppressor oncogene protein: p53; oncogene protein: p185 and age, hormone treatment, stage, and histologic grade.
    Nielsen AL; Nyholm HC
    Eur J Obstet Gynecol Reprod Biol; 1996 Dec; 70(1):79-85. PubMed ID: 9031925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of PTEN and β-Catenin and Their Relationship With Clinicopathological and Prognostic Factors in Endometrioid Type Endometrial Cancer.
    Sal V; Demirkiran F; Erenel H; Tokgozoglu N; Kahramanoglu I; Bese T; Turan H; Sofiyeva N; Calay Z; Arvas M; Guralp O
    Int J Gynecol Cancer; 2016 Mar; 26(3):512-20. PubMed ID: 26894937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
    Bildrici K; Tel N; Ozalp SS; Yalcin OT; Yilmaz V
    Eur J Gynaecol Oncol; 2002; 23(6):540-4. PubMed ID: 12556100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
    Fadare O; Parkash V
    Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.